Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109537 · ClinicalTrials.gov registry record
Altered Brain GABA and Glutamate in Restless Legs Syndrome
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 75
- Enrollment target
NCT01109537 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 75 participants.
The verdict
NCT01109537 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
The purpose of the study is to understand the brain chemistry of people with Restless Legs Syndrome (RLS). The primary hypothesis is that patients with RLS will have reduced GABA levels in their Thalamus and elevated Glutamate levels in their Anterior Cingulate Cortex. The study will use MRS imaging to examine the regional levels of these neurochemicals, GABA and Glutamate, in the brain.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2010-04 |
| Est. Completion | 2014-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109537
The ClinicalTrials.gov registry entry for NCT01109537 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01109537 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01109537 about?
NCT01109537 is a clinical study titled "Altered Brain GABA and Glutamate in Restless Legs Syndrome". The purpose of the study is to understand the brain chemistry of people with Restless Legs Syndrome (RLS). The primary hypothesis is that patients with RLS will have reduced GABA levels in their Thalamus and elevated Glutamate levels in their Anterior Cingulate Cortex. The study will use MRS imaging...
What is the current status of trial NCT01109537?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2010-04. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT01109537?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.